The Effect of Drugs and Genetic Factors on the Development and Progression of the Atherosclerotic Process

Author(s): Mišo Šabovič, Daniel Petrovič

Journal Name: Current Vascular Pharmacology

Volume 17 , Issue 1 , 2019

Become EABM
Become Reviewer
Call for Editor

Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet 2004; 364: 937-52.
Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European atherosclerosis society consensus panel. Eur Heart J 2017; 38: 2459-72.
McPherson R, Tybjaerg-Hansen A. Genetics of coronary artery disease. Circ Res 2016; 118: 564-78.
Wiegman A, Gidding SS, Watts GF, et al. European atherosclerosis society consensus panel. Familial hypercholesterolaemia in children and adolescents: Gaining decades of life by optimizing detection and treatment. Eur Heart J 2015; 36: 2425-37.
Nikpay M, Goel A, Won HH, et al. A comprehensive 1000 Genomes-based genome-wide association meta-analysis of coronary artery disease. Nat Genet 2015; 47: 1121-30.
Linsel-Nitschke P, Gotz A, Erdmann J, et al. Lifelong reduction of LDL-cholesterol related to a common variant in the LDL-receptor gene decreases the risk of coronary artery disease: A mendelian randomisation study. PLoS One 2008; 3: e2986.
Lewington S, Whitlock G, Clarke R, et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: A meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 2007; 370: 1829-39.
Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet 2010; 376: 1670-81.
Peterlin A, Petrovič D, Peterlin B. Screening for rare genetic variants associated with atherosclerosis: Opportunity for personalized medicine. Curr Vasc Pharmacol 2019; 17(1): 25-8.
Zimmet P, Alberti KG, Magliano DJ, Bennett PH. Diabetes mellitus statistics on prevalence and mortality: Facts and fallacies. Nat Rev Endocrinol 2016; 12: 616-22.
Nathan DM, Cleary PA, Backlund JY, et al. Diabetes control and complications trial/epidemiology of diabetes interventions and complications (DCCT/EDIC) study research group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 2643-53.
Choby B. Diabetes update: Prevention and management of diabetes complications. FP Essent 2017; 456: 36-40.
Lunder M, Janić M, Šabovič M. Prevention of vascular complications in diabetes mellitus patients: Focus on the arterial wall. Curr Vasc Pharmacol 2019; 17(1): 6-15.
Versari D, Daghini E, Virdis A, Ghiadoni L, Tadei S. Endothelial dysfunction as a target for prevention of cardiovascular disease. Diabetes Care 2009; 32(Suppl. 2): 314-21.
Janic M, Lunder M, Sabovic M. Arterial stiffness and cardiovascular therapy. BioMed Res Int 2015; 2015: 235709.
Vinkhuyzen AA, Wray NR, Yang J, Goddard ME, Visscher PM. Estimation and partition of heritability in human populations using whole- genome analysis methods. Annu Rev Genet 2013; 47: 75-95.
Ramuš-Mankoč S, Petrovič D. Genetic variations and subclinical markers of carotid atherosclerosis in patients with type 2 diabetes mellitus. Curr Vasc Pharmacol 2019; 17(1): 16-24.
Cole CB, Nikpay M, McPherson R. Gene-environment interaction in dyslipidemia. Curr Opin Lipidol 2015; 26: 133-8.
Sousa AG, Selvatici L, Krieger JE, Pereira AC. Association between genetics of diabetes, coronary artery disease, and macrovascular complications: Exploring a common ground hypothesis. Rev Diabet Stud 2011; 8: 230-44.
Machal J, Hlinomaz O. Efficacy of P2Y12 receptor blockers after myocardial infarction and genetic variability of their metabolic pathways. Curr Vasc Pharmacol 2019; 17(1): 35-40.
Boncelj Svetek M, Erzen B, Kanc K, Sabovic M. Impaired endothelial function and arterial stiffness in patients with type 2 diabetes - The effect of a very low-dose combination of fluvastatin and valsartan. J Diabetes Complications 2017; 31: 544-50.
Ford I, Murray H, McCowan C, Packard CJ. Long-term safety and efficacy of lowering low-density lipoprotein cholesterol with statin therapy: 20-year follow-up of west of Scotland coronary prevention study. Circulation 2016; 133: 1073-80.
Wang S, Head BP. Caveolin-1 in stroke neuropathology and neuroprotection: A novel molecular therapeutic target for ischemic-related injury. Curr Vasc Pharmacol 2019; 17(1): 41-50.
Fabjan A, Bajrović FF. Novel direct anticoagulants and atherosclerosis. Curr Vasc Pharmacol 2019; 17(1): 29-34.

free to download

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2019
Published on: 16 November, 2018
Page: [3 - 5]
Pages: 3
DOI: 10.2174/157016111701181101092855

Article Metrics

PDF: 26